Therapy‐resistant erythema of the rima ani

A 76-year-old patient presented to our outpatient clinic with a slowly growing, itchy and painful lesion of the rima ani. It developed about nine months ago, and the treatment with topical corticosteroids, antimycotic and antiseptic creams resulted in only moderate relief of the symptoms. The patient reported about a successful sclerotherapy of hemorrhoids several years ago and also about a partial resection of penis due to a squamous cell carcinoma of the glans in the year 2009. There were no further known skin diseases or allergies. A proctological examination had already been performed but did not reveal any pathological findings, in particular there was no indication of a recurrence of hemorrhoidal disease.

[1]  A. Idbaih,et al.  Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  B. Kreft,et al.  Cutaneous Langerhans cell histiocytosis – an indication for dermatological pharmacotherapy with topical nitrogen mustard , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[3]  R. Dummer,et al.  Histiocytosis – cutaneous manifestations of hematopoietic neoplasm and non‐neoplastic histiocytic proliferations , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  L. French,et al.  Individualized treatment approaches for Langerhans cell histiocytosis , 2018, The British journal of dermatology.

[5]  K. Hoang-Xuan,et al.  Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). , 2017, Blood.

[6]  H. Haenssle,et al.  Unilesional, single‐system cutaneous Langerhans cell histiocytosis in an 11‐month‐old infant , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[7]  M. Merad,et al.  Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? , 2015, British journal of haematology.

[8]  W. Hahn,et al.  Recurrent BRAF mutations in Langerhans cell histiocytosis. , 2010, Blood.

[9]  P. Itin,et al.  Unifocal Langerhans cell histiocytosis of the oral mucosa , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[10]  U. Pötschger,et al.  Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. , 2008, Blood.

[11]  U. Pötschger,et al.  Risk factors for diabetes insipidus in langerhans cell histiocytosis , 2006, Pediatric blood & cancer.

[12]  L. Lau,et al.  Cutaneous Langerhans cell histiocytosis in children under one year , 2006, Pediatric blood & cancer.

[13]  V. Meignin,et al.  [Adult Langerhans cell histiocytosis]. , 2017, Presse medicale.